Progenics Pharmaceuticals
Progenics Pharmaceuticals is a biopharmaceutical company based in Tarrytown, New York, focused on developing and commercializing innovative therapeutics for cancer and related conditions. The company's product pipeline includes several candidates such as Azedra, a radiotherapeutic for treating pheochromocytoma and paraganglioma; PyL and 1404, imaging agents for prostate cancer; and 1095, a treatment for metastatic castration-resistant prostate cancer currently in Phase II clinical trials. Additionally, Progenics is advancing PSMA ADC, a human monoclonal antibody-drug conjugate also in Phase II testing. The company offers Relistor, a first-in-class treatment for opioid-induced constipation, which is licensed for worldwide distribution, excluding Japan. Progenics also utilizes artificial intelligence technologies to enhance imaging analysis for prostate cancer diagnostics. Founded in 1986, Progenics collaborates with various partners, including Salix Pharmaceuticals for Relistor and Amgen for antibody development, reinforcing its commitment to advancing cancer care through targeted therapies and innovative technologies.
Top Stages
2 past transactions
Exini Diagnostics
Acquisition in 2015
EXINI Diagnostics AB is a Swedish company specializing in advanced software solutions for medical decision support, primarily focusing on image analysis for cancer diagnostics. Founded in 1999 and based in Lund, the company offers a range of software products, including EXINI bone for diagnosing prostate cancer through bone scintigraphy, EXINI heart for myocardial perfusion analysis, and EXINI brain for dementia diagnosis via cerebral blood flow scans. The company's technology is rooted in expert medical knowledge, sophisticated image analysis, and artificial neural networks, enabling automated and precise evaluations of diagnostic images. EXINI Diagnostics aims to enhance the accuracy and efficiency of medical practitioners in assessing conditions such as metastatic prostate cancer, thereby improving patient care outcomes.
Molecular Insight Pharmaceuticals
Acquisition in 2013
Molecular Insight Pharmaceuticals is a biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve patient healthcare by addressing significant unmet medical needs. They are focused on discovering, developing and commercializing innovative and targeted radiotherapeutics and molecular imaging pharmaceuticals with initial applications in the areas of oncology and cardiology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.